
Idinvest Partners
Description
Idinvest Partners, established in 1997, was a prominent pan-European private equity manager with a strong focus on the low and middle market segments. In 2018, it was fully acquired by Eurazeo, a leading global investment company, becoming a cornerstone of Eurazeo's private debt and venture capital activities. While no longer an independent entity, Idinvest's legacy and expertise continue to drive Eurazeo's strategies in these areas, particularly within the Eurazeo Venture and Eurazeo Growth divisions.
Historically, Idinvest Partners cultivated a diversified investment approach, encompassing venture capital, growth equity, private debt, and fund of funds. Its venture arm, now integrated into Eurazeo Venture, has been a significant player in the European tech ecosystem, targeting innovative companies across sectors such as digital, B2B software, and healthcare. The firm's pan-European footprint allowed it to identify and support high-potential businesses from early-stage development through significant growth phases.
For its venture and early-growth equity investments, Idinvest Partners, and subsequently Eurazeo Venture, typically deployed initial cheques ranging from €1 million to €20 million. This range supported companies from seed and Series A rounds up to more substantial growth capital infusions. Notable companies that have benefited from their investment include European success stories like Criteo, the global ad-tech giant, music streaming service Deezer, leading online healthcare platform Doctolib, and blockchain security firm Ledger. The firm's strategic capital and operational support have been instrumental in scaling these businesses across Europe and globally.
Investor Profile
Idinvest Partners has backed more than 412 startups, with 0 new investments in the last 12 months alone. The firm has led 190 rounds, about 46% of its total and boasts 128 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series Unknown, Series B, Series A rounds (top funding stages).
- Majority of deals are located in France, United States, Germany.
- Strong thematic focus on Health Care, Software, Biotechnology.
- Typical check size: $1M – $20M.
Stage Focus
- Series Unknown (30%)
- Series B (21%)
- Series A (19%)
- Series C (9%)
- Seed (8%)
- Series D (4%)
- Post Ipo Equity (2%)
- Series E (1%)
- Private Equity (1%)
Country Focus
- France (61%)
- United States (11%)
- Germany (5%)
- United Kingdom (4%)
- Spain (4%)
- Denmark (3%)
- The Netherlands (3%)
- Switzerland (2%)
- Belgium (1%)
- Sweden (1%)
Industry Focus
- Health Care
- Software
- Biotechnology
- Medical
- Apps
- Pharmaceutical
- Information Technology
- E-commerce
- Manufacturing
- Therapeutics
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.